比阿培南治疗淋巴瘤化疗后Ⅳ度骨髓抑制合并重度感染的临床疗效观察

Clinical efficacy of biapenem in the treatment of lymphoma patients with grade IV myelosuppression after chemotherapy combined with severe infection

目的评价淋巴瘤患者在化疗后Ⅳ度骨髓抑制期出现重度感染后应用比阿培南的疗效。方法回顾性分析在化疗后Ⅳ度骨髓抑制期出现重度感染后应用比阿培南的35例淋巴瘤患者资料，观察其临床疗效及不良反应。结果予比阿培南抗感染后，29例患者体温可降至正常，有效率为82．86％（29／35），未观察到明显的不良反应。结论比阿培南用于淋巴瘤治疗后Ⅳ度骨髓抑制期合并重度感染，安全、可靠，为有效的碳青霉烯类抗感染药物。

Objective To evaluate biapenem ＂s effect on lymphoma patients with grade IV myelosuppression after chemotherapy combined with severe infection. Methods Observe the clinical efficacy and untoward effect of patients with grade IV myelosuppression after chemotherapy who used biapenem through retrospective analysis of 35 patients. Results The temperature of 29 patients （82.86 %） with grade IV myelosuppression and infected severly was reduced to normal level after biapenem treatment, without untoward effect. Conclusion Biapenem is a kind of safe carbopenems medicine in the anti-infection treatment of lymphoma patients with grade IV myelosuppression after chemotherapy.